TSE:CTX Crescita Therapeutics (CTX) Stock Price, News & Analysis C$0.48 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Crescita Therapeutics Stock (TSE:CTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Crescita Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.49▼C$0.4950-Day RangeC$0.47▼C$0.5852-Week RangeC$0.45▼C$0.69VolumeN/AAverage Volume15,122 shsMarket CapitalizationC$8.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue. Read More Receive CTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescita Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTX Stock News HeadlinesCrescita Therapeutics Inc. (CTX.TO) - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.comCrescita Therapeutics First Quarter 2025 Earnings: CA$0.049 loss per share (vs CA$0.032 loss in 1Q 2024)May 16, 2025 | finance.yahoo.com3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. | Timothy Sykes (Ad)Crescita Reports First Quarter 2025 ResultsMay 14, 2025 | financialpost.comFCrescita Reports First Quarter 2025 ResultsMay 14, 2025 | financialpost.comFCrescita Therapeutics Inc. (CRRTF)November 24, 2024 | finance.yahoo.comChordia Therapeutics Advances Cancer Drug DevelopmentNovember 20, 2024 | markets.businessinsider.comPromising Phase 1 Results of Compass Therapeutics’ CTX-471 Highlight Potential for Advanced Solid Tumors TreatmentNovember 11, 2024 | markets.businessinsider.comSee More Headlines CTX Stock Analysis - Frequently Asked Questions How have CTX shares performed this year? Crescita Therapeutics' stock was trading at C$0.58 at the beginning of 2025. Since then, CTX stock has decreased by 16.4% and is now trading at C$0.49. How do I buy shares of Crescita Therapeutics? Shares of CTX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Crescita Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescita Therapeutics investors own include Baytex Energy (BTE), Argonaut Gold (AR), Birchcliff Energy (BIR), CBTX (CBTX), Crescent Point Energy (CPG), Enbridge (ENB) and IMV (IMV). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CTX CIKN/A Webwww.crescitatherapeutics.com Phone+1-905-6734295FaxN/AEmployees62Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$2.61 million Net Margins-15.73% Pretax MarginN/A Return on Equity-15.60% Return on Assets-8.26% Debt Debt-to-Equity Ratio5.77 Current Ratio2.70 Quick Ratio2.29 Sales & Book Value Annual SalesC$16.62 million Price / Sales0.54 Cash FlowC$0.40 per share Price / Cash Flow1.20 Book ValueC$0.83 per share Price / Book0.58Miscellaneous Outstanding Shares18,406,184Free FloatN/AMarket CapC$8.93 million OptionableNot Optionable Beta1.69 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (TSE:CTX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescita Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescita Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.